Neurotoxicity of commonly used antineoplastic agents (second of two parts).
D000125:Achilles Tendon / Q000187:drug effects; D000818:Animals; D000970:Antineoplastic Agents / Q000633:toxicity*; D001341:Autonomic Nervous System / Q000187:drug effects; D002493:Central Nervous System Diseases / Q000139:chemically induced; D003391:Cranial Nerves / Q000187:drug effects; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006689:Hodgkin Disease / Q000188:drug therapy; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy; D009043:Motor Activity / Q000187:drug effects; D009420:Nervous System / Q000187:drug effects*; D009422:Nervous System Diseases / Q000139:chemically induced*; D009461:Neurologic Manifestations; D009588:Nitrogen Mustard Compounds / Q000627:therapeutic use / Q000633:toxicity; D010292:Paresthesia / Q000139:chemically induced; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced; D011344:Procarbazine / Q000627:therapeutic use / Q000633:toxicity; D012026:Reflex, Stretch / Q000187:drug effects; D012640:Seizures / Q000139:chemically induced; D014667:Vasopressins / Q000378:metabolism; D014747:Vinblastine / Q000633:toxicity; D014750:Vincristine / Q000628:therapy / Q000633:toxicity
D000970:Antineoplastic Agents; D009588:Nitrogen Mustard Compounds; D014667:Vasopressins; D011344:Procarbazine; D014750:Vincristine; D014747:Vinblastine